2,596.00
+1.66%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About RPG Life Sciences
Its shares trade on NSE under the ticker RPGLIFE.NS. It has been listed since 10 June 2008. In the fiscal year to 31 March 2026, it reported revenue of ₹7.08bn and net income of ₹1.15bn. At that date it held total assets of ₹7.93bn and shareholders' equity of ₹6.05bn.
RPG Life Sciences Ltd. is engaged in the development, manufacture, and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2008-06-10. The firm operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jun 2008
- Employees
- 1,165
Leadership
Pay as last reported
- Mr. Harsh GoenkaNon-Executive Non-Independent Chairman of the Board₹500,000
- Mr. Amol LoneChief Financial Officer
- Ms. Sheetal GabaChief Human Resources Officer
- Mr. Rajesh ShirambekarHead - Legal, Compliance Officer, Company Secretary
- Shri. Mahesh NarayanaswamyVice President - Finance
- Mr. Ashok NairManaging Director, Director, since 2025
- Mr. Rajat BhargavaNon-Executive Director₹775,000
- Mr. Manoj MaheshwariAdditional Non-Executive Non-Independent Director, since 2024₹500,000
- Ms. Vasundhara PatniNon-Executive Non-Independent Director
- Ms. Radhika GuptaAdditional Non-Executive Independent Director
- Mr. Bhaskar IyerNon-Executive Independent Director₹745,000
- Ms. Zahabiya KhorakiwalaNon-Executive Independent Director₹415,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- RPG Life Sciences Ltd. operates in over 10 therapeutic areas including oncology and cardiology.
- The company manufactures and markets branded formulations in India across multiple therapeutic segments.
- RPG Life Sciences has a strong presence in international formulations and APIs for regulated markets.
Weaknesses
- The company's domestic formulations business focuses on India, limiting global market reach.
- RPG Life Sciences relies on a limited product portfolio including Azoran and Mofetyl.
- The firm's international formulations business faces competition in emerging markets.
Opportunities
- RPG Life Sciences can expand its presence in the growing oncology market segment.
- The company can leverage its API manufacturing capabilities for international expansion.
- RPG Life Sciences has potential to grow in the respiratory and diabetology therapeutic areas.
Threats
- RPG Life Sciences faces regulatory challenges in emerging markets for international formulations.
- The company's reliance on a few key products like Azoran and Mofetyl poses a risk.
- RPG Life Sciences must navigate increasing competition in the Indian pharmaceutical market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.